• The effectiveness of the use of Etanercept immunobiological preparation in children with rheumatoid arthritis
To content

The effectiveness of the use of Etanercept immunobiological preparation in children with rheumatoid arthritis

SOVREMENNAYA PEDIATRIYA. 2015.1(65):72-82; doi 10.15574/SP.2015.65.72

 

The effectiveness of the use of Etanercept immunobiological preparation in children with rheumatoid arthritis

 

Berezhnoi V. V.

P.L. Shupik National Medical Academy of Postgraduate Education, Kiev, Ukraine

 

The modern approaches to the treatment of rheumatoid arthritis in children are presented in the review. The results of numerous studies on the efficacy and safety of the Etanercept preparation in the treatment of present disease are shown.

 

Key words: rheumatoid arthritis, children, treatment, Etanercept.

 

REFERENCES

1. Алексеева ЕИ, Валиева СИ, Бзарова ТМ, Денисова РВ. 2011Метотрексат «золотой стандарт» лечения ювенильного ревматоидного артрита. Вопр совр педиатрии. 10(1): 42–49.

2. Алексеева ЕИ, БзароваТМ, Валиева СИ. 2012. Эффективность и безопасность человеческих моноклональных антител к ФНО-a у детей с ювенильным идиопатическим apтpитом при первичной и вторичной неэффективности других генно-инженерных биологических препаратов. Вопр совр педиатрии. 11(4): 82–88.

3. Баранов АА, Алексеева ЕИ, Валиева СИ и др. 2013. Биологическая терапия в педиатрической ревматологии. Вопр совр педиатрии. 10(1): 5–16.

4. Бзарова ТМ, Алексеева ЕИ, Васильева СИ и др. 2010. Безопасность применения ингибиторов факторов некроза опухоли альфа во взрослой и детской ревматологической практике. Вопр совр педиатр. 9(1): 2–15.

5. Жолобова ЕС, Чебышева СН, Геппe HA и др. 2011. Клиннико-рентгенологическая динамика у пациента с системной формой ювенильного ревматоидного артрита на терапии этанерцентом. Леч. врач. 4: 83–5.

6. Коваленко ВН, Борткевич ОП, Белявская ЮВ. 2013. Новая стратегия терапии ревматоидного артрита (на основании пересмотра рекомендаций Европейской антиревматической лиги по лечению синтетическими и биологическими базисными болезнь-модифицирующими антиревматическими препаратами). Украинский ревматологический журнал. 454(4).

7. Конопелько ОЮ и др. 2012. Эффективность этанерцепта в лечении различных вариантов ювенильного идиопатического артрита: 115–119.

8. Лучихина ЕЛ, Каратеев ДЕ. 2008. Ранняя диагностика РА: проблемы и решения. Рос мед вестн. 4: 21–25.

9. Никишина ИП. 2009. Растворимые рецепторы к фактору некроза опухоли (этанерцепт) в терапии ювенильного артрита. Рус мед журн. 17(3): 2–7.

10. Юрьев КЛ. 2012. Сравнительная эффективность и безопасность лекарственных средств: данные систематических обзоров DERP. Укр мед часопис. 6(92): 90–96.

11. Balsa A, de Miguel E, Castillo C et al. 2010. Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard. Rheumatology (Oxford). 49(4): 683–90. DOI: 10.1093 /rheumatology/kep442. Epub 2010 Jan 4.

12. Breda L, Del Torto M, De Sanctis S, Chiarell F. 2011. Biologics in children's autoimmune disorders: Efficacy and safety. Eur J Pediatr. 170: 157–167.

13. Cassidy JT, Petty RE, Laxer RM et al. 2010. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders Elsevier: 794.

14. De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. 1991. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 34: 1158–63.

15. Fries JF, Bloch DA, Sharp JT, McShane DJ, Spitz P, Bluhm GB, Forrester D, Genant H, Gofton P, Richman S et al. 1986, Jan. Assessment of radiologic progression in rheumatoid arthritis. A randomized, controlled trial. Arthritis Rheum. 29(1): 1–9.

16. Gartner M, Mandl P, Radner H et al. 2013.Sonographic joint assessment in rheumatoid arthritis: Associations with clinical joint assessment in remission. Arthritis Rheum. 65(8): 2005–14. DOI: 10.1002 /art.38016.

17. Genant HK. 1983. Methods of assessing radiographic change in rheumatoid arthritis. Am J Med. 75: 35–47.

18. Genant HK, Jiang Y, Peterfy C, Lu Y, Redei J, Countryman PJ. 1998. Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum. 41: 1583–1590.

19. Giannini E, llowite N, Lovell O, Wallace C, Rabinonch C, Reiff A, Higgins G, Gottlieb B, Chon Y, Lin S-L. 2008. The long-term safety of etanercept (Enbrel®) in children with polyarticular or systemic juvenile rheumatoid arthritis. Interim results of a 3-year, open-label registry. Оral presentation. ACR Keystone Pediatric Rheumatology Symposium; 1–5 March 2008; Keystone.

20. Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A et al. 2009. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 60(9): 2794–804. http://dx.doi.org/10.1002/art.24777; PMid:19714630

21. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group. 2006. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 48: 2122–2127.

22. Guillemin F, Oedegaard S, G?rard N, Billot L, Boini S, Kvien TK. 2001. Reproducibility and sensitivity to change of 5 scoring methods for hand X-ray damage in rheumatoid arthritis. Аbstract. Ann Rheum Dis. 59; suppl I: 214.

23. Hjardem E, Оstergaard M, Podenphant J et al. 2007. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor? Ann Rheum Dis. 66: 1184–9.

24. Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ et al. 2004. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 63: 1638–44.

25. Horneff G, DeBock F, Foeldvari Т, Girschick HJ et al. 2008. Safety and efficacy of combination of Etanercept and Methotrexate compared to treatment with Etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA Registry. Ann Rheum Dis. Published online 15 Apr 2008; doi: 10.1136/ard.2007.087593.

26. Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, Schmeling H. 2008. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA registry. Ann Rheum Dis.

27. Horneff G, Schmeling H, Biedermann T et al. for the Paediatric Rheumatology Collaborative Group. 2011. The German Etanercept Registry for Treatment of Juvenile Idiopathic Arthritis. Ann Rheum Dis. 63: 1638–44.

28. Hyrich KL, Lunt M, Watson KD, Symmons D, Silman AJ. 2007. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 56(1): 13–20. eScholarID:1d15592 |DOI:10.1002/art.22331. http://dx.doi.org/10.1002/art.22331

29. Keul R, Heinrich PC, Muller-Newen G, Muller K, Woo P. 1998. A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis. Cytokine. 10: 729-34.

30. Kietz DA, Pepmueller PH, Moore TL. 2001. Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis. J Rheumatol. 28: 360–362.

31. Kievit W, Adang EM, Fransen J et al. 2008. The effectiveness and medication costs of three anti-TNFa agents in the treatment of rheumatoid arthritis from prospective clinical practice data. ARD. 5: 75.

32. Kimura Y, Pinho P, Walco G et.al. 2005. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol. 32: 935–42.

33. Lovell DJ, Giannini EH, Reiff A et al. 2000. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 16;342(11): 763–769.

34. Lovell DJ, Giannini E.H, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, llowite NT, Wallace CA, Whitmore J, Finck BK. 2000. Etanercept in children with polyarticular juvenile rheumatoid arthritis, pediatric rheumatology collaborative study group. N Engl J Med. 342: 763–769.

35. Lovell DJ, Giannini EH, Reiff A et al. 2000. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 16;342(11): 763–769.

36. Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC et al. 2003. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open!label, extended!treatment trial. Arthritis Rheum. 48: 218–26.

37. Lovell DJ, Reiff A, Jones OY, Schneider П, Nocton J, Stein LO er al. 2006. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 54: 1987–94.

38. Lovell DJ, Reiff A, Jones OY, Schneider R et al. 2006. Long-term safety and efficacy of etanercept in children with polyarticular!course juvenile rheumatoid arthritis. Arthritis Rheum. 54: 1987–1994.

39. Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, Baumgartner SW, Giannini EH, Pediatric Rheumatology Collaborative Study Group. 2008. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 58: 1496–1504.

40. Lovell DJ, Reiff A, Ilowite NТ, Wallace CA et al. 2008. Safety and efficacy of up to eight years of continuous Etanercept therapy in patients with Juvenile rheumatoid arthritis. Arthritis Rheum. 58;5: 1496–1504.

41. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, Nemcova D, Mouy R, Sandborg C, Bohnsack J, Elewaut D, Foeldvari I, Gerloni V, Rovensky J, Minden K, Vehe RK, Weiner LW, Horneff G, Huppertz HI, Olson NY, Medich JR, Carcereri-De-Prati R, Mcllraith MJ, Giannini EH, Martini A, Pediatric Rheumatology Collaborative Study Group, Pediatric Rheumatology International Trials Organisation. 2008. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 359: 810–820.

42. Lovell DJ, Reiff A, Ilowite NТ, Wallace CA et al. 2008. Safety and efficacy of up to eight years of continuous Etanercept therapy in patients with Juvenile rheumatoid arthritis. Arthritis Rheum. 58;5: 1496–1504.

43. Otten M, Prince F, Twilt M et al. 2010. Delaed clinical response in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol. 37: 665–667.

44. Pain C, McCann L. 2009. Challenges in the management of juvenile idiopathic arthritis with etanercept. Biologics: Targets & Therapy. 3: 127–139.

45. Prince F?HM, Twilt M, ten Cate R, Van Rossum M?AJ et al. 2009. Long-term follow!up on effectiveness and safety of etanercept in JIA: the Dutch national register. Ann Rheum Dis. Published online 15 Apr 2009 doi: 10.1136/ard.2007,087411.

46. Rooney M, David J, Symons J, Di Giovine F, Varsani H, Woo P. 1995. Inflammatory cytokine responses in juvenile chronic arthritis. Br J Rheumatol. 34: 454–60.

47. Sakellariou G, Scire CA, Verstappen SM et.al. 2013. In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis. Ann Rheum Dis. 72(7): 245–9. DOI: 10.1136/annrheumdis-2012 — 201–817. Epub2012 Oct 11.

48. Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S et al. 2005. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 53(1): 18–23. http://dx.doi.org/10.1002/art.20904; PMid:15696578

49. Tynjala P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. 2007. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis. 66(4): 548–50. http://dx.doi.org/10.1136/ard.2006.058248; PMid:17068061 PMCid:PMC1856052

50. Van der Heijde DM, Wolfe F, Larsen A. 2000. Assessing radiographic status of reumatoid arthritis: introduction of a short erosion scale. J Rheumarol. 27: 2090–2099.

51. Van der Heijde DM, Lassere M, Boers M, et. al. 1999. Smallest detectable difference in radiological progression. J Rheumarol. 26: 731–739.

52. Prince FHM, Twilt M, ten Cate R. 2009. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch nation al register. Ann Rheum Dis. 68: 635–641.

53. Horneff G, Schmeling H, Biedermann T. 2004. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 63: 1638–1644.

54. Minden K, Niewerth M, Zink A. 2012. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology. 51: 1407-1415